Cargando…

Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide

BACKGROUND: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elimination procedure using cholestyramine or activate...

Descripción completa

Detalles Bibliográficos
Autores principales: Filali-Ansary, Aziz, Lunven, Catherine, Turpault, Sandrine, Beyer, Yann-Joel, O'Brien, Amy, Delfolie, Astrid, Boyanova, Neli, Sanderink, Ger-Jan, Baldinetti, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949010/
https://www.ncbi.nlm.nih.gov/pubmed/27015245
http://dx.doi.org/10.1097/FTD.0000000000000302
_version_ 1782443365656166400
author Filali-Ansary, Aziz
Lunven, Catherine
Turpault, Sandrine
Beyer, Yann-Joel
O'Brien, Amy
Delfolie, Astrid
Boyanova, Neli
Sanderink, Ger-Jan
Baldinetti, Francesca
author_facet Filali-Ansary, Aziz
Lunven, Catherine
Turpault, Sandrine
Beyer, Yann-Joel
O'Brien, Amy
Delfolie, Astrid
Boyanova, Neli
Sanderink, Ger-Jan
Baldinetti, Francesca
author_sort Filali-Ansary, Aziz
collection PubMed
description BACKGROUND: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elimination procedure using cholestyramine or activated charcoal may be used. The current bioanalytical assay for determination of plasma teriflunomide concentration requires laboratory facilities for blood centrifugation and plasma storage. An alternative method, with potential for greater convenience, is dried blood spot (DBS) methodology. Analytical and clinical validations are required to switch from plasma to DBS (finger-prick sampling) methodology. METHODS: Using blood samples from healthy subjects, an LC-MS/MS assay method for quantification of teriflunomide in DBS over a range of 0.01–10 mcg/mL was developed and validated for specificity, selectivity, accuracy, precision, reproducibility, and stability. Results were compared with those from the current plasma assay for determination of plasma teriflunomide concentration. RESULTS: Method was specific and selective relative to endogenous compounds, with process efficiency ∼88%, and no matrix effect. Inaccuracy and imprecision for intraday and interday analyses were <15% at all concentrations tested. Quantification of teriflunomide in DBS assay was not affected by blood deposit volume and punch position within spot, and hematocrit level had a limited but acceptable effect on measurement accuracy. Teriflunomide was stable for at least 4 months at room temperature, and for at least 24 hours at 37°C with and without 95% relative humidity, to cover sampling, drying, and shipment conditions in the field. The correlation between DBS and plasma concentrations (R(2) = 0.97), with an average blood to plasma ratio of 0.59, was concentration independent and constant over time. CONCLUSIONS: DBS sampling is a simple and practical method for monitoring teriflunomide concentrations.
format Online
Article
Text
id pubmed-4949010
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Therapeutic Drug Monitoring
record_format MEDLINE/PubMed
spelling pubmed-49490102016-08-03 Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide Filali-Ansary, Aziz Lunven, Catherine Turpault, Sandrine Beyer, Yann-Joel O'Brien, Amy Delfolie, Astrid Boyanova, Neli Sanderink, Ger-Jan Baldinetti, Francesca Ther Drug Monit Original Article BACKGROUND: Teriflunomide, a once-daily oral immunomodulator approved for treatment of relapsing-remitting multiple sclerosis, is eliminated slowly from plasma. If necessary to rapidly lower plasma concentrations of teriflunomide, an accelerated elimination procedure using cholestyramine or activated charcoal may be used. The current bioanalytical assay for determination of plasma teriflunomide concentration requires laboratory facilities for blood centrifugation and plasma storage. An alternative method, with potential for greater convenience, is dried blood spot (DBS) methodology. Analytical and clinical validations are required to switch from plasma to DBS (finger-prick sampling) methodology. METHODS: Using blood samples from healthy subjects, an LC-MS/MS assay method for quantification of teriflunomide in DBS over a range of 0.01–10 mcg/mL was developed and validated for specificity, selectivity, accuracy, precision, reproducibility, and stability. Results were compared with those from the current plasma assay for determination of plasma teriflunomide concentration. RESULTS: Method was specific and selective relative to endogenous compounds, with process efficiency ∼88%, and no matrix effect. Inaccuracy and imprecision for intraday and interday analyses were <15% at all concentrations tested. Quantification of teriflunomide in DBS assay was not affected by blood deposit volume and punch position within spot, and hematocrit level had a limited but acceptable effect on measurement accuracy. Teriflunomide was stable for at least 4 months at room temperature, and for at least 24 hours at 37°C with and without 95% relative humidity, to cover sampling, drying, and shipment conditions in the field. The correlation between DBS and plasma concentrations (R(2) = 0.97), with an average blood to plasma ratio of 0.59, was concentration independent and constant over time. CONCLUSIONS: DBS sampling is a simple and practical method for monitoring teriflunomide concentrations. Therapeutic Drug Monitoring 2016-08 2016-07-25 /pmc/articles/PMC4949010/ /pubmed/27015245 http://dx.doi.org/10.1097/FTD.0000000000000302 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Original Article
Filali-Ansary, Aziz
Lunven, Catherine
Turpault, Sandrine
Beyer, Yann-Joel
O'Brien, Amy
Delfolie, Astrid
Boyanova, Neli
Sanderink, Ger-Jan
Baldinetti, Francesca
Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide
title Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide
title_full Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide
title_fullStr Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide
title_full_unstemmed Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide
title_short Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide
title_sort dried blood spot methodology in combination with liquid chromatography/tandem mass spectrometry facilitates the monitoring of teriflunomide
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949010/
https://www.ncbi.nlm.nih.gov/pubmed/27015245
http://dx.doi.org/10.1097/FTD.0000000000000302
work_keys_str_mv AT filaliansaryaziz driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide
AT lunvencatherine driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide
AT turpaultsandrine driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide
AT beyeryannjoel driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide
AT obrienamy driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide
AT delfolieastrid driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide
AT boyanovaneli driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide
AT sanderinkgerjan driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide
AT baldinettifrancesca driedbloodspotmethodologyincombinationwithliquidchromatographytandemmassspectrometryfacilitatesthemonitoringofteriflunomide